^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Excerpt:
...a patient with the recalcitrant G1202R mutation had a confirmed PR in the ALTA trial.
DOI:
10.2147/DDDT.S147499